Literature DB >> 23891426

Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation.

Adi Butnaru1, Joseph Shaheen, Dan Tzivoni, Rachel Tauber, Daniel Bitran, Shuli Silberman.   

Abstract

Bioprosthetic valve thrombosis is uncommon and the diagnosis is often elusive and may be confused with valve degeneration. We report our experience with mitral bioprosthetic valve thrombosis and suggest a therapeutic approach. From 2002 to 2011, 149 consecutive patients who underwent mitral valve replacement with a bioprosthesis at a single center were retrospectively screened for clinical or echocardiographic evidence of valve malfunction. Nine were found to have valve thrombus. All 9 patients had their native valve preserved, representing 24% of those with preserved native valves. Five patients (group 1) presented with symptoms of congestive heart failure at 16.4 ± 12.4 months after surgery. Echocardiogram revealed homogenous echo-dense film on the ventricular surface of the bioprosthesis with elevated transvalvular gradient, resembling early degeneration. The first 2 patients underwent reoperation: valve thrombus was found and confirmed by histologic examination. Based on these, the subsequent 3 patients received anticoagulation treatment with complete thrombus resolution: mean mitral gradient decreased from 23 ± 4 to 6 ± 1 mm Hg and tricuspid regurgitation gradient decreased from 83 ± 20 to 49 ± 5 mm Hg. Four patients (group 2) were asymptomatic, but routine echocardiogram showed a discrete mass on the ventricular aspect of the valve: 1 underwent reoperation to replace the valve and 3 received anticoagulation with complete resolution of the echocardiographic findings. In conclusion, bioprosthetic mitral thrombosis occurs in about 6% of cases. In our experience, onset is early, before anticipated valve degeneration. Clinical awareness followed by an initial trial with anticoagulation is warranted. Surgery should be reserved for those who are not responsive or patients in whom the hemodynamic status does not allow delay. Nonresection of the native valve at the initial operation may play a role in the origin of this entity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23891426     DOI: 10.1016/j.amjcard.2013.06.014

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Unnatural milieu: Thrombus after transcatheter mitral valve replacement.

Authors:  Jaffar M Khan; Robert J Lederman
Journal:  Catheter Cardiovasc Interv       Date:  2017-08-01       Impact factor: 2.692

2.  Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation.

Authors:  Philipp Ruile; Nikolaus Jander; Philipp Blanke; Simon Schoechlin; Jochen Reinöhl; Michael Gick; Juergen Rothe; Mathias Langer; Jonathon Leipsic; Heinz-Joachim Buettner; Franz-Josef Neumann; Gregor Pache
Journal:  Clin Res Cardiol       Date:  2016-11-16       Impact factor: 5.460

3.  Transcatheter mitral valve replacement: still a long way to go!

Authors:  Thierry Carrel
Journal:  Ann Transl Med       Date:  2017-09

Review 4.  Transcatheter Mitral Valve Therapy: Defining the Patient Who Will Benefit.

Authors:  Marvin H Eng; Dee Dee Wang
Journal:  Curr Cardiol Rep       Date:  2018-09-12       Impact factor: 2.931

5.  Recurrent bioprosthetic mitral valve thrombosis treated with anticoagulation.

Authors:  Robin Fernandes; Anubodh S Varshney; Jayashri Aragam
Journal:  Echocardiography       Date:  2020-10-27       Impact factor: 1.724

6.  Human menopausal gonadotropin-induced bioprosthetic valve thrombosis.

Authors:  Rami Mahmood Abazid; Mohamed Shoman; Osama A Smettie; Osama A Elamin
Journal:  Avicenna J Med       Date:  2018 Jul-Sep

7.  A Case of Bioprosthetic Mitral Valve Dysfunction, Initially Presenting with Valve Thrombosis Followed by Recurrent Thrombosis and Endocarditis.

Authors:  Eirini Apostolidou; Charles Beale; Athena Poppas; Philip Stockwell; Afshin Ehsan
Journal:  CASE (Phila)       Date:  2019-07-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.